BioWorld

Dec. 9, 2002

BIO Revises Corn Policy, Further Revision Possible

U.S. Patent Disclosure

Appointments And Advancements

Other News To Note

A Streamlining Curis Licenses Out PYY Technology For $15M

Curis Inc. last week shed certain assets as part of an ongoing realignment, while licensing out its second program in about a week's time and simultaneously cutting jobs. (BioWorld Today) Read More

Public Mouse Genome Draft Done, Comparisons Begin

Today's news in brief

BioWorld

BioWorld briefs for Aug. 8, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for August 7, 2025.

Gregory Verdine, founder and CEO, Dovetree

Xtalpi finalizes $6B AI drug discovery deal with Dovetree

BioWorld

Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with Dovetree LLC on Aug. 6. The...

Eyes on the prize: FDA approves Lenz’s drops for presbyopia

BioWorld

With the U.S. FDA’s approval of Lenz Therapeutics Inc.’s Vizz (aceclidine ophthalmic solution), there is a third eye drop on the market for treating presbyopia....

Results of lithium orotate vs. lithium carbonate on amyloid-β and tau

Lithium could change Alzheimer's care, but not all forms work

BioWorld Science

The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments. Scientists focused on amyloid-β...